INVO Fertility has realigned its leadership to accelerate a clinic-focused growth strategy. Terah Krigsvold, previously the company’s controller, has been promoted to chief financial officer, while former CFO Andrea Goren moves into a deal-driven remit as chief business officer and chief executive of INVO Centers LLC, the subsidiary that houses the company’s fertility clinics. The shift positions Goren to lead acquisitions and new clinic launches as INVO pursues a broader roll-up of fertility services and ancillary operations alongside ongoing distribution of its INVOCELL device and intravaginal culture procedure.
The move is a clear signal that INVO intends to convert finance expertise into transaction velocity while preserving continuity in core accounting. More strategically, it underscores a transition from a device-led story to a services-centric model where clinic ownership is the growth engine and the device is the differentiator. In a sector where patient demand is rising but unit economics hinge on capacity, payor mix, and employer benefits, owning the site of care rather than just supplying it offers greater control over pricing, experience, and outcomes data.
Timing matters. Fertility remains a largely cash-pay, consumer-influenced market, but employer-sponsored coverage is expanding and more states are enacting infertility mandates, reshaping access and reimbursement. INVO’s pitch centers on delivering a lower-cost alternative to traditional IVF by using INVOCELL-enabled intravaginal culture, which reduces laboratory footprint and could enable clinic expansion into price-sensitive or underserved geographies. If the model can demonstrate comparable outcomes and a differentiated patient experience, it creates an economic wedge for employers and payers seeking affordability without sacrificing efficacy. That, in turn, raises the bar for evidence: Medical Affairs will need to generate real-world data on live-birth rates, patient selection, and adherence, and to equip HCPs with protocols and counseling frameworks to integrate IVC into practice where appropriate.
The leadership reshuffle also reflects broader consolidation and verticalization across fertility services. Private equity-backed platforms are racing to acquire clinics, integrate laboratory operations, and lock in referral flows through employer benefit managers and digital front doors. Devices and services are converging as companies seek to capture more of the margin stack and insulate against procurement pressure. Clinic models that are less lab-intensive could mitigate workforce bottlenecks and operating costs, a nontrivial advantage in a capacity-constrained market. At the same time, policy volatility around reproductive care, combined with tighter capital markets, favors operators that can prove resilient unit economics and rapid payback on clinic build-outs. Placing a seasoned finance leader over business development and subsidiary operations suggests INVO is prioritizing diligence, contracting, and post-merger integration as competitive levers.
What should stakeholders watch next? Scale and density will be decisive: with two operational INVO Centers in the U.S. and one IVF clinic, the company needs to show that acquisition and de novo openings can reach profitability quickly while maintaining clinical quality. For payers and employers, the question is whether real-world evidence will justify distinct coverage tiers for IVC, potentially unlocking formulary-like steering in a services setting. For HCPs, clarity on protocols, candidate selection, and outcome comparability will drive adoption. Competitors must decide whether to incorporate IVC within their portfolios or double down on full-service IVF platforms. For pharma companies in reproductive health, any shift in stimulation intensity, cycle mix, or total volume could subtly reshape demand for gonadotropins and adjunct therapies. The next year will reveal whether a device-enabled, vertically integrated clinic strategy can carve out durable advantage against larger, capital-rich fertility networks.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
